Very long-term remission with azacitidine in VEXAS syndrome
Not available.
Saved in:
Main Authors: | Lin-Pierre Zhao, Vincent Jachiet, Olivier Kosmider, Lise Larcher, Emmanuelle Clappier, Marie Sébert, Lionel Adès, Pierre Hirsch, Thibault Mahévas, Maxime Battistella, Jean-David Bouaziz, Arsène Mekinian, Pierre Fenaux, MINHEMON FRENVEX |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11923 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
by: Jorge E. Cortes, et al.
Published: (2025-01-01) -
Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
by: Kazuya Sato, et al.
Published: (2021-01-01) -
VEXAS, Chediak–Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?
by: Coline Savy, et al.
Published: (2025-01-01) -
Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01) -
Conquering myositis, beyond remission
by: Amber O'Connor, et al.
Published: (2020-01-01)